Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 4/20 | 0.48 |
| ▸ | KDM5A | P29375 | 3/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.48 |
| ▸ | KDM4A | O75164 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | PRKAA2 | P54646 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | FAAH | O00519 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3622032 | 0.81 | RBP4 (0.45) | KDM5BKDM5AKDM4CRBP4LMNA | |
| SCHEMBL754518 | 0.74 | KDM5A (0.52) | KDM5BKDM5AKDM4CKDM4ARBP4 | |
| SCHEMBL3617437 | 0.74 | MAPT (0.37) | KDM4CALDH1A1PRKAA2LMNA | |
| SCHEMBL8177003 | 0.74 | ALDH1A1 (0.48) | KDM5BKDM5AKDM4CKDM4AALDH1A1 | |
| SCHEMBL3612911 | 0.74 | ALDH1A1 (0.48) | KDM5BKDM5AKDM4CKDM4AALDH1A1 | |
| SCHEMBL16921555 | 0.71 | GRM2 (0.45) | KDM5BKDM5AKDM4CKDM4ARBP4 | |
| SCHEMBL7185653 | 0.69 | KDM5A (0.53) | KDM5BKDM5AKDM4CKDM4ARBP4 | |
| SCHEMBL15964744 | 0.66 | RBP4 (0.54) | KDM5BKDM5AKDM4CKDM4ARBP4 | |
| SCHEMBL765397 | 0.66 | KDM5B (0.48) | KDM5BKDM5AKDM4CKDM4AALDH1A1 | |
| SCHEMBL19149495 | 0.66 | MAPT (0.55) | ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304438-B2 | Heteroarylacrylamides and their use as pharmaceuticals | SANOFI (FR) | 2012-11-06 | — | — | US | disclosed |
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2010-01-21 | — | — | US | disclosed |
| EP-2099753-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis (FR) | 2009-09-16 | — | — | EP | disclosed |
| EP-1939180-A1 | Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2008074413-A2 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS FOR THE STIMULATION OF THE EXPRESSION OF ENDOTHELIAL NO SYNTHASE | SANOFI-AVENTIS (FR) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016272-A1 | HETEROARYLACRYLAMIDES AND THEIR USE AS PHARMACEUTICALS | NOS3, PTGIS, NOS1 | KDM5B 2026/4885KDM5A 1433/4885KDM4C 2809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.